PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28086800-13	2017	Furthermore, GW4064 induced the expression of small heterodimer partners (SHP) and suppressed liver X receptor (LXR)-induced steatosis in hepatocytes, expecting the in vivo protective effect of FXR on liver injury especially with steatosis.	GW 4064	13-19	nuclear receptor subfamily 0, group B, member 2	Mus musculus	74-77	
28086800-15	2017	The key molecules, p62/SQSTM1, Nrf2 and SHP were upregulated in fatty liver tissue by GW4064 treatment.	GW 4064	86-92	nuclear receptor subfamily 0, group B, member 2	Mus musculus	40-43	
27609522-7	2016	Treatment of pregnant mice with GW4064 induced ileal Fgf15, Shp and Ostalpha/beta mRNAs, and restored hepatic Shp, Bal, Ntcp, and Bsep back to vehicle-treated virgin levels.	GW 4064	32-38	nuclear receptor subfamily 0, group B, member 2	Mus musculus	60-63	
27609522-7	2016	Treatment of pregnant mice with GW4064 induced ileal Fgf15, Shp and Ostalpha/beta mRNAs, and restored hepatic Shp, Bal, Ntcp, and Bsep back to vehicle-treated virgin levels.	GW 4064	32-38	nuclear receptor subfamily 0, group B, member 2	Mus musculus	110-113	
25926433-7	2015	In CYP2D6-humanized transgenic mice, GW4064 decreased hepatic CYP2D6 expression and activity (by 2-fold) while increasing SHP expression (by 2-fold) and SHP recruitment to the CYP2D6 promoter.	GW 4064	37-43	nuclear receptor subfamily 0, group B, member 2	Mus musculus	122-125	
27127878-6	2016	Moreover, the experiments on tumor-bearing mice showed that GW4064/CDDP co-treatment inhibited the tumor growth in vivo by up-regulating SHP expression and down-regulating STAT3 phosphorylation.	GW 4064	60-66	nuclear receptor subfamily 0, group B, member 2	Mus musculus	137-140	
25926433-7	2015	In CYP2D6-humanized transgenic mice, GW4064 decreased hepatic CYP2D6 expression and activity (by 2-fold) while increasing SHP expression (by 2-fold) and SHP recruitment to the CYP2D6 promoter.	GW 4064	37-43	nuclear receptor subfamily 0, group B, member 2	Mus musculus	153-156	
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	21-27	nuclear receptor subfamily 0, group B, member 2	Mus musculus	45-48	
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	125-131	nuclear receptor subfamily 0, group B, member 2	Mus musculus	45-48	
25926433-8	2015	CYP2D6 repression by GW4064 was abrogated in Shp(-/-);CYP2D6 mice, indicating a critical role of SHP in CYP2D6 regulation by GW4064.	GW 4064	125-131	nuclear receptor subfamily 0, group B, member 2	Mus musculus	97-100	
25926433-10	2015	This proof of concept study provides evidence for CYP2D6 regulation by an inducer of SHP expression, namely, the FXR agonist GW4064.	GW 4064	125-131	nuclear receptor subfamily 0, group B, member 2	Mus musculus	85-88	
32258949-8	2020	FXR-targeted gene small heterodimer partner (SHP) was critical for the regulation of KC response by GW4064.	GW 4064	100-106	nuclear receptor subfamily 0, group B, member 2	Mus musculus	45-48	
18385139-7	2008	Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1alpha to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA.	GW 4064	23-29	nuclear receptor subfamily 0, group B, member 2	Mus musculus	85-88